Research progress of Qifu yin in the treatment of Alzheimer’s disease with marrow-sea insufficiency syndrome
- VernacularTitle:七福饮治疗髓海不足型阿尔茨海默病的研究进展
- Author:
Zilong WEI
1
;
Chenyi ZHAO
2
;
Mingliang QIAO
2
;
Hongwei WANG
1
;
Pei ZHU
1
;
Yi MENG
2
Author Information
1. The Second Clinical Medical College，Henan University of Chinese Medicine，Zhengzhou 450002，China
2. Dept. of Geriatrics，Henan Provincial Hospital of Traditional Chinese Medicine，Zhengzhou 450002，China
- Publication Type:Journal Article
- Keywords:
Qifu yin;
Alzheimer’s disease;
marrow-sea insufficiency;
mechanism of action;
clinical research
- From:
China Pharmacy
2026;37(10):1376-1380
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer’s disease （AD） is an age-related neurodegenerative disorder. Marrow-sea insufficiency serves as the fundamental basis for the onset of AD. Early syndrome differentiation-based intervention helps to delay disease progression， and improve patients’ cognitive function. Qifu yin is a representative specialized prescription for AD with marrow-sea insufficiency syndrome. Studies demonstrate that Qifu yin exerts neuroprotective effects through multiple pathways， including inhibiting the abnormal deposition of amyloid β -protein and hyperphosphorylation of tau protein， alleviating neuroinflammation， regulating oxidative stress and mitochondrial dysfunction， modulating the cholinergic system， and improving synaptic plasticity. Qifu yin combined with Western medicine such as donepezil， memantine， and butylphthalide， or combined with external therapies such as acupuncture， can effectively improve cognitive function and activities of daily living in AD patients with favorable safety. Future research should focus on the core pathogenesis and key targets of AD with marrow-sea insufficiency syndrome， provide in-depth elucidation of the scientific connotation of Qifu yin’s “tonifying the kidney to produce marrow”， and further conduct high-quality clinical studies to provide scientific evidence for the prevention and treatment of AD with marrow-sea insufficiency syndrome.
